DUBLIN--(BUSINESS WIRE)--The "Hunter Syndrome Treatment Market Analysis by Treatment (Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT)), and by Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
The global hunter syndrome treatment market size is estimated to be USD 995.71 million in 2021 and is expected to witness a CAGR of 7.83% during the forecast period.
Increase in number of patients suffering from hunter syndrome is a key driver for the growth of the global hunter syndrome treatment market.
Additionally, the rise in initiatives taken up by the governments, introduction of novel therapies in the market, and occurrence of strong pipeline portfolio are some of the other drivers propelling the market growth.
Nevertheless, the increasing cost of treatment and lack of awareness about hunter syndrome treatment are expected to restrain the global market growth.
The hunter syndrome treatment market report is categorized into the following segments and subsegments:
By Treatment (Revenue, USD Million, 2021-2029)
- Hematopoietic Stem Cell Transplant (HSCT)
- Enzyme Replacement Therapy (ERT)
- Others
By Region (Revenue, USD Million, 2021-2029)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Companies Mentioned
- Takeda Pharmaceutical Company (Japan)
- GC Pharma (South Korea)
- JCR Pharmaceuticals Co Ltd. (Japan)
- RegenxBio Inc. (U.S.)
- Sangamo Therapeutics Inc. (U.S.)
- ArmaGen Inc. (U.S.)
- Inventiva S.A. (France)
- Denali Therapeutics Inc. (U.S.)
- Bioasis Technologies Inc. (Canada)
- Avrobio Inc. (U.S.)
For more information about this report visit https://www.researchandmarkets.com/r/gtd8tm
